Cyclooxygenase Isoforms and Platelet Vessel Wall Interactions in the Apolipoprotein E Knockout Mouse Model of Atherosclerosis

Circulation

Volumn 108, Issue 24, 2003, Pages 3017-3023

  Belton, Orina A ^a   Duffy, Angela ^a   Toomey, Sinead ^a   Fitzgerald, Desmond J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Apoptosis; Atherosclerosis; Platelets

Indexed keywords

2,3 DINOR 6 OXOPROSTAGLANDIN F1 ALPHA; 2,3 DINORTHROMBOXANE B2; 4 [5 (4 CHLOROPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]BENZENESULFONAMIDE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; APOLIPOPROTEIN E; CD40 LIGAND; CD68 ANTIGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; FIBRINOGEN RECEPTOR; ISOENZYME; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; PROTEIN BAX; THROMBOXANE;

ANIMAL MODEL; ANIMAL TISSUE; ARTERY LESION; ARTICLE; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CELL ACTIVITY; CHOLESTEROL DIET; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE;

ANIMALS; ANTIGENS, CD; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; BCL-2-ASSOCIATED X PROTEIN; BLOOD PLATELETS; BLOOD VESSELS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; ISOENZYMES; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0347625842     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000104565.78013.AD     Document Type: Article

References (28)

1. Belton O, Byrne D, Kearney D, et al. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102:840-845.
2. Schonbeck U, Sukhova GK, Graber P, et al. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 1999;155:1281-1291.
3. McGeer PL, McGeer EG, Yasojima K. Expression of COX-1 and COX-2 mRNAs in atherosclerotic plaques. Exp Gerontol. 2002;37:925-929.
4. Clarke RJ, Mayo G, Price P, et al. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991;325:1137-1141.
5. Funk CD, Funk LB, Kennedy ME, et al. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J. 1991;5:2304-2312.
6. FitzGerald GA, Smith B, Pedersen AK, et al. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med. 1984;310:1065-1068.
7. Reilly IA, Doran JB, Smith B, et al. Increased thromboxane biosynthesis in a human preparation of platelet activation: biochemical and functional consequences of selective inhibition of thromboxane synthase. Circulation. 1986;73:1300-1309.
8. Cyrus T, Sung S, Zhao L, et al. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation. 2002;106:1282-1287.
9. Cipollone F, Prontera C, Pini B, et al. Overexpression of functionally coupled cyclooxygenase-2 and prostaglandin E synthase in symptomatic atherosclerotic plaques as a basis of prostaglandin E(2)-dependent plaque instability. Circulation. 2001;104:921-927.
10. Connolly E, Bouchier-Hayes DJ, Kaye E, et al. Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty. J Pharmacol Exp Ther. 2002;300:393-398.
11. Cheng Y, Austin SC, Rocca B, et al. Role of prostacyclin in the cardiovascular response to thromboxane A2. Science. 2002;296:539-541.
12. Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002;196:887-896.
13. Cullen L, Kelly L, O'Connor S, et al. Selective cyclooxygenase-2 inhibition by nimesulide in man. J Pharmacol Exp Ther. 1998;287:578-582.
14. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999;289:735-741.
15. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med. 2000;343:1520-1528.
16. Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation. 2002;105:1816-1823.
17. Pratico D, Tillmann C, Zhang ZB, et al. Acceleration of atherogenesis by COX-1-dependent prostanoid formation in low density lipoprotein receptor knockout mice. Proc Natl Acad Sci U S A. 2001;98:3358-3363.
18. Rott D, Zhu J, Burnett MS, et al. Effects of MF-tricyclic, a selective COX-2 inhibitor, on atherosclerosis progression and susceptibility to CMV replication in ApoE knockout mice. J Am Coll Cardiol. 2003;41:1812-1819.
19. Fitzgerald DJ, Roy L, Catella F, et al. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983-989.
20. Fitzgerald DJ, Rocki W, Murray R, et al. Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet. 1990;335:751-754.
21. Cayatte AJ, Du Y, Oliver-Krasinski J, et al. The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apo E-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:1724-1728.
22. Paul A, Calleja L, Camps J, et al. The continuous administration of aspirin attenuates atherosclerosis in apolipoprotein E-deficient mice. Life Sci. 2000;68:457-465.
23. Mach F, Schonbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998;394:200-203.
24. Schwabe RF, Schnabl B, Kweon YO, et al. CD40 activates NF-kappa B and c-Jun N-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol. 2001;166:6812-6819.
25. Cipollone F, Mezzetti A, Porreca E, et al. Association between enhanced soluble CD40L and prothrombotic state in hypercholesterolemia: effects of statin therapy. Circulation. 2002;106:399-402.
26. Lutgens E, Gorelik L, Daemen MJ, et al. Requirement for CD154 in the progression of atherosclerosis. Nat Med. 1999;5:1313-1316.
27. Kockx MM, De Meyer GR, Muhring J, et al. Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation. 1998;97:2307-2315.
28. Yao PM, Tabas I. Free cholesterol loading of macrophages is associated with widespread mitochondrial dysfunction and activation of the mitochondrial apoptosis pathway. J Biol Chem. 2001;276:42468-42476.